Oracle Health Sciences Introduces New Cloud-Based eClinical Platform
DIA – Chicago, IL. – Jun 19, 2017 – Oracle today introduced Oracle Health Sciences Clinical One Platform, a cloud-based eClinical platform that is intended to redefine the way technology supports clinical research, and its first capability, Oracle Health Sciences Clinical One Randomization and Supplies Management Cloud Service.
Developing a potentially life-saving drug from a promising molecule to an FDA-approved therapy can take more than a decade and cost billions of dollars due to redundant processes, increasing volumes and variety of patient data and older technology systems that don’t talk to one another. Oracle Health Sciences is tackling these issues with Clinical One, a new cloud-based eClinical solution that will unify clinical development operations and information on a single platform with shared functions and an easy-to-use interface for clinical coordinators and their counterparts.
Unlike existing point solutions that address only a single part of the drug development lifecycle or a single area within clinical research, Clinical One is a holistic, unified platform that is being built from the ground-up to address the needs of the entire drug development lifecycle – everyone and every process required to get a drug to market. The vision for Clinical One is to bring more drugs to market faster and offer hope for more cures by eliminating redundancies, creating process efficiencies and sharing information - in a way that has never been done before.
“Pharmaceutical companies continue to look for new and innovative ways to bring therapies to market faster and more cost effectively. Technology providers who can offer a unified, cloud-based eClinical platform that enables companies to seamlessly share clinical trial data throughout all phases of the drug development lifecycle and across all functions, will be poised to take advantage of the expanding eClinical market,” said Alan S. Louie, Ph.D., Research Director, IDC.
In addition to unveiling its Clinical One Platform, Oracle also launched its first capability on the new platform, Oracle Health Sciences Clinical One Randomization and Supplies Management Cloud Service. Designed with self-service in mind, the planned new capability features an intuitive user interface, enabling clinical teams to design, validate and deploy a study in days with the click of a button. By eliminating the need for customization, clinical coordinators can quickly add patients to a trial collect screening information and ensure eligibility for randomization in record time.
“The pharmaceutical industry has been stitching together systems to support the clinical development lifecycle for decades, creating a Frankenstein effect. Our vision, and why we created the Clinical One Platform, is we intend to provide our life sciences customers with a modern, collaborative environment that eliminates massive redundancies and help enable them to set up a trial in days versus weeks, while allowing broader clinical teams to leverage what’s already been done,” said Steve Rosenberg, general manager, Oracle Health Sciences. “But ultimately, it’s about trying to accelerate the pace of finding more cures faster and more cost-effectively as millions of patients wait with hope.”
About Oracle
The Oracle Cloud delivers hundreds of SaaS applications and enterprise-class PaaS and IaaS services to customers in more than 195 countries while processing 55 billion transactions a day. For more information about Oracle (NYSE:ORCL), please visit us at http://cloud.oracle.com.
Trademarks
Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.
The preceding is intended to outline our general product direction. It is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. The development, release and timing of any features or functionality described for Oracle's products remains at the sole discretion of Oracle.
Contacts
Valerie Beaudett Christina McDonald
Oracle Corporation Burson-Marsteller
+1 650.400.7833 +1 212.614.4221
Valerie.beaudett@oracle.com Christina.McDonald@bm.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
